Collectively, the findings in our study demonstrated that the promising novel anti-tumor agent, DpdtC that can up-regulate NDRG1 and target HER2-ERK1/2 pathway, has the potential to provide a new therapeutic strategy in HER2-overexpressing cancer treatment. Here, MAPK3 is linked to neoplasm.